At its highest dose, Eli Lilly’s experimental drug retatrutide cut body weight by 25% on average in a late-stage trial


The drug acts on three appetite and blood-sugar hormones instead of one or two. The results were published in the New England Journal of Medicine. The trial did not compare retatrutide with existing drugs, and it was too small to measure rarer safety risks.
Retatrutide is an experimental obesity drug developed by Eli Lilly. In a late-stage clinical trial, people on the highest dose lost an average of 25% of their body weight after 80 weeks. For those who continued in an extension period to 104 weeks, the average loss reached 30%. Overall, more than a third of participants taking retatrutide lost 30% or more of their weight. The results were published on September 29, 2026, in the New England Journal of Medicine, according to Ars Technica.
Ars Technica described retatrutide as expected to be the most powerful obesity drug yet and said the results appear to meet those high expectations. The trial itself cannot settle that ranking, however, because it did not test retatrutide against any existing drug.
The trial began in 2023. It enrolled 2,339 people with obesity at 131 clinical trial sites in 11 countries. Participants were split into four nearly equal groups. Three groups received weekly retatrutide at 4 mg, 9 mg or 12 mg. The fourth received a placebo, a dummy treatment with no active drug. On average, participants started at about 113 kg (250 pounds). Their average body mass index (BMI), a measure of weight relative to height, was 40, well within the obese range.
Today's leading obesity drugs mimic hormones that the gut releases after a meal. Novo Nordisk's semaglutide (sold as Ozempic and Wegovy) mimics GLP-1. Lilly's tirzepatide (sold as Zepbound for obesity and Mounjaro for type 2 diabetes) mimics both GLP-1 and a second hormone, GIP. Retatrutide adds a third hormone: glucagon.
These three hormones have overlapping jobs. They help control blood sugar, the feeling of fullness and how much a person eats. GLP-1 increases insulin release, slows how fast the stomach empties and signals fullness to the brain. GIP also stimulates insulin, helps break down triglycerides (a type of fat in the blood) and acts in the brain to promote fullness. Glucagon comes from the pancreas and partly works against the other two. It triggers the release of sugar and fatty acids into the blood when blood sugar drops too low. After meals, however, it also appears to help with insulin production, slower stomach emptying and fat regulation.
Retatrutide's active ingredient is a single lab-made peptide, a short chain of amino acids. Different parts of the molecule attach to the receptors for each of the three hormones. It binds less strongly than the body's own GLP-1 and glucagon but nearly nine times more strongly than natural GIP. The peptide is stabilized so it stays active in the blood for about six days, which allows once-weekly injections.
The researchers also looked at smaller groups of participants with conditions linked to obesity. Among 574 people with knee osteoarthritis, the drug reduced knee pain by up to 62%. Among 243 people with obstructive sleep apnea, a condition in which breathing repeatedly stops during sleep, it cut the number of these events per hour by up to 57%.
Measures of heart and metabolic health improved across the board, including blood pressure, triglycerides and LDL ("bad") cholesterol. More than a third of participants had prediabetes at the start, meaning their blood sugar was above normal but not yet at diabetes levels. By the end, the condition had resolved in more than 90% of them.
The trial compared retatrutide only with a placebo, not with an existing treatment such as tirzepatide. Whether retatrutide beats current drugs on weight loss or other health benefits will need to be tested in future trials.
So far, the drug's safety looks similar to that of existing GLP-1 and GLP-1/GIP drugs. The most common complaints were temporary, mild-to-moderate digestive problems such as nausea, diarrhea and constipation. Some participants felt dizzy or had low blood pressure. This was more common among people already taking blood pressure medication.
Rarer problems remain unresolved. Ten participants had cardiovascular events, one of them in the placebo group. There were also 10 reports of pancreatitis, an inflammation of the pancreas, two of them in the placebo group. The study was not large enough to show whether retatrutide raises the risk of either problem. Larger, longer trials are needed to answer that question.
Correction ·
House style applied: Armenian punctuation, date and money forms.
Correction ·
Corrected spelling and punctuation in the Armenian text.
Correction ·
Corrected the wording of the English version.